Fusosome Gene Delivery With Liver-Specific Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering large biologic agents into cells is challenging due to the plasma membrane barrier, and existing methods face issues with immune response activation and non-specific transgene expression, leading to limited durability and off-target effects.
Innovation Solution
Fusosomes, comprising a lipid bilayer with a fusogen and nucleic acid encoding a payload gene regulated by liver-specific and non-liver cell-specific elements, enhance targeted delivery and expression while minimizing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fusosomes use constitutive promoters for transgene expression, then transgene expression is achieved, but immune response activation occurs and expression durability is limited
Solution Approach 1:
The patent applies local quality by using tissue-specific promoters (liver-specific promoters like Albumin, APOE, or HNF1A promoters) to drive transgene expression only in liver cells rather than constitutively in all cells. This localized expression approach ensures that the therapeutic transgene is expressed specifically in the target tissue (liver) while avoiding expression in non-target cells that would trigger immune responses. The miRNA target sequences are also designed with local quality in mind, being placed specifically in the 3' UTR region of the transgene cassette to provide cell-type specific regulation without affecting promoter function.
Solution Approach 2:
The patent implements preliminary anti-action by incorporating miRNA target sequences into the transgene cassette before transgene expression begins. These miRNA target sequences (complementary to liver-specific miRNAs like miR-122, miR-192, or miR-214) are designed to suppress transgene expression in non-target cells that express these miRNAs, thereby preventing immune response activation in advance. The regulatory elements are built into the fusosome structure beforehand to preemptively block harmful effects before they occur.
2Productivity
If fusosomes deliver transgenes to non-target cells, then broad distribution is achieved, but off-target effects and immune clearance occur
Solution Approach 1:
The patent uses local quality by designing regulatory elements that provide spatial specificity to transgene expression. Liver-specific promoters ensure that even when fusosomes are distributed broadly throughout the body, transgene expression occurs only in liver cells where the promoter is active. Additionally, miRNA target sequences provide a second layer of local quality control by suppressing expression in any non-hepatocytic cells that might accidentally take up the fusosome, thus eliminating off-target effects while maintaining broad delivery capability.
Solution Approach 2:
The patent employs miRNA regulatory elements as intermediaries between the transgene and the cellular environment. These miRNA target sequences act as mediators that interpret the cellular context and selectively allow or block transgene expression based on the presence or absence of specific miRNAs in different cell types. This intermediary mechanism enables the fusosome to deliver transgenes broadly while intelligently restricting functional expression to the correct cell type, preventing off-target effects.
3Quantity of substance
If fusosomes use strong constitutive promoters, then high transgene expression is achieved, but immune response and neutralizing antibody generation occur
Solution Approach 1:
The patent replaces strong constitutive promoters with liver-specific promoters that provide adequate expression levels specifically in hepatocytes without causing overexpression in other cell types. The liver-specific promoters (such as Albumin, APOE, or HNF1A promoters) are optimized to drive high-level expression in the target liver cells while maintaining tissue specificity. This approach achieves sufficient therapeutic expression levels in the correct cells without triggering the immune response that would result from widespread expression in non-target cells.
Solution Approach 2:
The patent converts the potential harm of miRNA-mediated suppression in non-target cells into a benefit by using the same miRNA targeting mechanism to enhance liver-specific expression. By designing miRNA target sequences that are complementary to liver-specific miRNAs, the system creates a dual regulatory mechanism: it suppresses expression in non-hepatocytic cells (preventing immune response) while simultaneously enhancing expression in hepatocytes where these miRNAs are naturally abundant. This converts what could be a harmful suppression mechanism into a beneficial tool for achieving high liver-specific expression without immune clearance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Fusosomes achieve stable, long-term expression of therapeutic transgenes in liver cells with reduced immune activation and minimal off-target effects, ensuring high specificity and durability.
Implementation Method 1
the fusosome comprises a lipid bilayer with a fusogen
Implementation Method 2
nucleic acid encoding a payload gene regulated by liver-specific and non-liver cell-specific elements
Data Source
AI summary
The present disclosure provides, at least in part, methods and compositions for in vivo fusosome delivery. In some embodiments, the fusosome comprises a combination of elements that promote specificity for target cells, e.g., one or more of a fusogen, a positive target cell-specific regulatory element, and a non-target cell-specific regulatory element. In some embodiments, the fusosome comprises one or more modifications that decrease an immune response against the fusosome.